Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Sees Significant Decrease in Short Interest

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) saw a large decrease in short interest in the month of October. As of October 15th, there was short interest totaling 647 shares, a decrease of 98.4% from the September 30th total of 39,624 shares. Based on an average daily volume of 102,484 shares, the days-to-cover ratio is presently 0.0 days.

Ono Pharmaceutical Trading Down 0.5%

Ono Pharmaceutical stock traded down $0.02 during midday trading on Monday, reaching $5.25. 42,501 shares of the company’s stock were exchanged, compared to its average volume of 37,629. Ono Pharmaceutical has a 52 week low of $3.82 and a 52 week high of $5.75. The stock’s 50-day simple moving average is $5.04 and its 200 day simple moving average is $5.01.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd. is a Japan-based, research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its activities focus primarily on areas of high unmet medical need, including oncology, immunology, neurology and other specialty-care fields.

The company’s best-known product is Opdivo (nivolumab), an immune checkpoint inhibitor used in the treatment of multiple cancers. Ono has also developed or commercialized other specialty medicines, including treatments for cancer and immune-related conditions, through internal research and collaborations with pharmaceutical companies in Japan and overseas.

Ono Pharmaceutical traces its origins to 1717, when it began as a drug wholesaler in Osaka, and was incorporated in its modern corporate form in 1947.